Precision System Science Co., Ltd., together with its subsidiaries, develops, manufactures, and sells automated systems and instruments, other physicochemical instruments, software, and other products in Japan, North America, Europe, and internationally. The company offers magLEAD 12gC LiNK, an automated nucleic acid extraction system. It also provides extraction reagents comprising MagDEA Dx SV, a prefilled reagent cartridge for magnetic bead-based nucleic acid extractions; MagDEA Dx MVII, a highly concentrated nucleic acid extraction reagent for viral nucleic acid extraction of cfNDA extraction; and MagDEA Dx SV RNA, a total RNA extraction reagent, as well as MagDEA Dx LV. In addition, the company offers fully automated PCR systems consisting of geneLEAD XII plus and geneLEAD VIII, which are fully automated sample-to-sample result instruments for molecular testing. Further, it provides research reagents, including LeeChip 45-uni, a lectin microarray for glycan profiling analysis; plastic consumables; and electronic equipment. The company's products are used for research and development, as well as for the in vitro diagnosis (IVD) testing market, including genetic and protein tests. Precision System Science Co., Ltd. was incorporated in 1985 and is headquartered in Matsudo, Japan.
Research context
Precision System Science Co., Ltd appears in PyInvesting’s Tokyo Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- JPY
- Sector
- Healthcare
- Industry
- Medical Devices
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Precision System Science Co., Ltd is currently in a long term downtrend where the price is trading 20.2% below its 200 day moving average.
From a valuation standpoint, the stock is 94.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.6.
Precision System Science Co., Ltd's total revenue rose by 121.3% to $2B since the same quarter in the previous year.
Its net income has increased by 269.9% to $159M since the same quarter in the previous year.
Based on the above factors, Precision System Science Co., Ltd gets an overall score of 3/5.